Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GU-216: A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)

NCT06050954 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT06050954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06050954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GU-216: A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2023
Completion date
January 31, 2032
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial carcinoma